The CAM family: A new target for monitoring or treating cancers?

Publication date : 2019-08-28

The cell adhesion molecules (CAMs) family includes more than 50 proteins with four main groups: immunoglobulin (Ig)-like CAMs, cadherins, selectins, and integrins.

Diaclone has been interested for many years in adhesion molecules and can provide monoclonal antibodies against all of the selectin and integrin families, most of the IgSF CAM family and also EpCAM, H-CAM, M-CAM and BL-CAM.

These monoclonal antibodies include, amongst others, Anti-Human CD31, CD50, CD54, CD66a, CD102, CD106, CD62…

Knowing that the soluble form levels could become an innovative tool of cancer monitoring, Diaclone has also developed ELISA kits for measuring serum levels of a wide range of sCAMs:

I-CAM-1 (human CD54 ELISA kit), I-CAM-2 (human CD102 ELISA kit), I-CAM-3 (human CD50 ELISA kit), VCAM-1 (human CD106 ELISA kit), PECAM-1 (CD31 ELISA kit), …

Find out more...




Other news

  • CAR-T development
    CAR-T development
    Publication date : 2019-10-01
    How can Diaclone support your CAR-T development? Read more
  • New Diaclone Catalogue!
    New Diaclone Catalogue
    Publication date : 2019-09-05
    Diaclone is pleased to present its new catalogue! Just click and discover.... Read more
  • Diaclone est partenaire d’un projet européen d’envergure associant une douzaine de partenaires de la région de Besançon.
    MiMédi Project
    Publication date : 2019-08-29
    Diaclone is a partner in a major European project involving a dozen partners from the Besançon region. Read more
  • Assays for the Human IL-17 Family
    DIACLONE Assays for the Human IL-17 Family
    Publication date : 2019-08-28
    Diaclone has developed a large range of ELISA and ELISpot kits for the detection of Human IL-17A, IL-17F and IL-17A/F. Read more
  • PSL
    PSL Alliance
    Publication date : 2019-08-28
    Diaclone is a core member of the PSL Alliance Read more
  • Smaltis
    SMALTIS joins the Biotech Investissement Group!
    Publication date : 2019-08-28
    We are pleased to announce the entry of Biotech Investissement into the capital of SMALTIS SAS, a company based in Besançon (France), which joins RD-Biotech SAS, Diaclone SAS, SynAbs SA and QVQ Holding within the group ( Read more

Product search